CA2526128C - Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation - Google Patents
Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation Download PDFInfo
- Publication number
- CA2526128C CA2526128C CA 2526128 CA2526128A CA2526128C CA 2526128 C CA2526128 C CA 2526128C CA 2526128 CA2526128 CA 2526128 CA 2526128 A CA2526128 A CA 2526128A CA 2526128 C CA2526128 C CA 2526128C
- Authority
- CA
- Canada
- Prior art keywords
- ctg
- aac
- gcc
- ttc
- gtg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47082003P | 2003-05-16 | 2003-05-16 | |
US60/470,820 | 2003-05-16 | ||
US48250503P | 2003-06-26 | 2003-06-26 | |
US60/482,505 | 2003-06-26 | ||
US10/843,656 | 2004-05-12 | ||
US10/843,656 US8080642B2 (en) | 2003-05-16 | 2004-05-12 | Severe acute respiratory syndrome DNA compositions and methods of use |
PCT/US2004/015512 WO2005021707A2 (fr) | 2003-05-16 | 2004-05-17 | Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2526128A1 CA2526128A1 (fr) | 2005-03-10 |
CA2526128C true CA2526128C (fr) | 2013-07-30 |
Family
ID=34279761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA 2526128 Expired - Fee Related CA2526128C (fr) | 2003-05-16 | 2004-05-17 | Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation |
Country Status (5)
Country | Link |
---|---|
US (1) | US8080642B2 (fr) |
EP (2) | EP1633853A4 (fr) |
CA (1) | CA2526128C (fr) |
SG (1) | SG2009050212A (fr) |
WO (1) | WO2005021707A2 (fr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
EP1578193A4 (fr) * | 2002-12-23 | 2011-06-15 | Vical Inc | Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique |
AU2003293196A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
US20070270361A1 (en) * | 2003-08-04 | 2007-11-22 | Shan Lu | Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof |
ES2396127T3 (es) * | 2003-12-02 | 2013-02-19 | Institut Pasteur | Uso de proteinas y peptidos codificados por el genoma de una nueva cepa de coronavirus asociado al SRAS |
WO2006071250A2 (fr) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Fragments solubles de la glycoproteine de spicule de cov-sras |
TWI293957B (en) | 2004-07-21 | 2008-03-01 | Healthbanks Biotech Co Ltd | A superantigen fusion protein and the use thereof |
US20060134221A1 (en) * | 2004-12-03 | 2006-06-22 | Vical Incorporated | Methods for producing block copolymer/amphiphilic particles |
US20060123499A1 (en) * | 2004-12-06 | 2006-06-08 | Donglai Wu | Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof |
EP1749833A1 (fr) | 2005-08-05 | 2007-02-07 | Healthbanks Biotech Co., Ltd. | Superantigènes dérivés de la protéine à pointe E2 du coronavirus du SRAS |
CA2658484A1 (fr) | 2006-07-20 | 2008-01-24 | Vical Incorporated | Compositions et methodes de vaccination contre le hsv-2 |
GB0711858D0 (en) * | 2007-06-19 | 2007-07-25 | Glaxosmithkline Biolog Sa | Vaccine |
US8513005B2 (en) * | 2007-07-09 | 2013-08-20 | The United States Of America As Represented By The Secretary Of The Army | DNA immunogenic composition comprising a full-length modified poxvirus L1R gene fused to a tPA leader sequence |
US7807180B2 (en) | 2007-08-21 | 2010-10-05 | University Of Massachusetts | Poxvirus methods and compositions |
US20110184160A1 (en) * | 2010-01-26 | 2011-07-28 | Weiner David B | Nucleic acid molecule encoding consensus influenza a hemagglutinin h1 |
US8298820B2 (en) | 2010-01-26 | 2012-10-30 | The Trustees Of The University Of Pennsylvania | Influenza nucleic acid molecules and vaccines made therefrom |
WO2012116715A1 (fr) * | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des nouveaux-nés et des enfants en bas âge |
WO2012116714A1 (fr) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination chez des patients âgés |
EP2839841A1 (fr) * | 2013-08-19 | 2015-02-25 | Veterinärmedizinische Universität Wien | Vaccin d'adénovirus aviaire |
EP2839838A1 (fr) | 2013-08-19 | 2015-02-25 | Veterinärmedizinische Universität Wien | Vaccin d'adénovirus aviaire |
EP3452101A2 (fr) * | 2016-05-04 | 2019-03-13 | CureVac AG | Arn codant pour une protéine thérapeutique |
IL295482A (en) * | 2020-02-14 | 2022-10-01 | Geovax Inc | Vaccines and their uses to induce an immune response to sars-cov2 |
WO2021168427A1 (fr) * | 2020-02-20 | 2021-08-26 | The Trustees Of Columbia University In The City Of New York | Compositions et procédés pour la détection rapide de sars-cov-2 |
TW202146435A (zh) * | 2020-03-04 | 2021-12-16 | 美商昂科賽醫藥公司 | 含有病原性抗原及免疫刺激物之組合物 |
US20230136960A1 (en) * | 2020-03-19 | 2023-05-04 | Nature's Toolbox, Inc. | Novel MRNA-Based COVID-19 Multi-Valent Vaccine and Methods of Scaled Production of the Same |
WO2021188818A1 (fr) * | 2020-03-19 | 2021-09-23 | The United States Of America As Represented By The Secretary Of The Navy | Constructions de vaccin et compositions et procédés d'utilisation de celles-ci |
RU2759227C2 (ru) * | 2020-04-10 | 2021-11-11 | Генетик Диагностикс Энд Терапи 21 Лтд | ДНК-вакцина против вируса SARS-CoV-2 на основе генотерапевтического ДНК-вектора GDTT1.8NAS12, способ ее получения, штаммы, несущие генотерапевтические ДНК-вектора, способ их получения, способ производства в промышленных масштабах генотерапевтических ДНК-векторов |
KR20230005265A (ko) * | 2020-04-23 | 2023-01-09 | 자이두스 라이프사이언시즈 리미티드 | Sars-cov-2에 대한 백신 및 이의 제조 |
EP4153227A4 (fr) * | 2020-05-18 | 2024-07-03 | Univ California | Vaccin à plate-forme à vecteur unique, puissant et sûr contre la covid -19 |
WO2021248053A2 (fr) * | 2020-06-04 | 2021-12-09 | Godx, Inc. | Dispositif de diagnostic du virus sars-cov-2 au point de soins et procédés d'utilisation de celui-ci |
CN111620952A (zh) * | 2020-06-17 | 2020-09-04 | 苏州米迪生物技术有限公司 | 基于嵌合型病毒样颗粒的新型冠状病毒疫苗 |
EP4175666A1 (fr) | 2020-07-03 | 2023-05-10 | Statens Serum Institut | Vaccin à adn plasmidique anti-sras-coronavirus -2/covid-19 |
WO2022067062A1 (fr) * | 2020-09-24 | 2022-03-31 | Epivax, Inc. | Développement rapide d'un vaccin prophylactique à large spectre pour le sars-cov-2 à l'aide d'un système d'administration d'antigène à médiation par phage |
CN112575008B (zh) * | 2020-12-31 | 2023-03-24 | 四川大学华西医院 | 编码新型冠状病毒的结构蛋白的核酸分子以及新型冠状病毒疫苗 |
US20220226489A1 (en) | 2021-01-20 | 2022-07-21 | Singh Biotechnology, Llc | Therapeutics directed against coronavirus |
Family Cites Families (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
EP0173494A3 (fr) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Récepteurs chimériques par liaison et expression de l'ADN |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
US4597966A (en) * | 1985-01-09 | 1986-07-01 | Ortho Diagnostic Systems, Inc. | Histidine stabilized immunoglobulin and method of preparation |
US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
EP0218625B1 (fr) * | 1985-03-29 | 1995-04-05 | Btg International Limited | Proteine "pointe" du virus de la bronchite infectieuse |
EP0247091B1 (fr) | 1985-11-01 | 1993-09-29 | Xoma Corporation | Assemblage modulaire de genes d'anticorps, anticorps ainsi prepares et utilisation |
US5143726A (en) * | 1986-12-09 | 1992-09-01 | The Scripps Research Institute | T cell epitopes of the hepatitis B virus nucleocapsid protein |
EP0448605A4 (en) | 1988-12-15 | 1991-11-21 | Invitron Corporation | Use of basic amino acids to solubilize immunoglobulins |
GB8903313D0 (en) | 1989-02-14 | 1989-04-05 | Wellcome Found | Conjugates |
US6867195B1 (en) * | 1989-03-21 | 2005-03-15 | Vical Incorporated | Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
EP0489033B1 (fr) * | 1989-08-22 | 1994-10-19 | Veterinary Infectious Disease Organization | Polypeptides de coronavirus bovins et vaccins contre ce virus |
ATE93271T1 (de) * | 1989-11-28 | 1993-09-15 | Wellcome Found | Vakzine. |
US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
DK0510773T3 (da) * | 1991-04-25 | 2004-04-19 | Akzo Nobel Nv | Canine coronavirus subunit-vaccine |
US5643578A (en) * | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
US6429199B1 (en) * | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
US6207646B1 (en) * | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
FR2724385B1 (fr) * | 1994-08-29 | 1996-12-13 | Rhone Merieux | Vaccin de la peritonite infectieuse feline. |
US5656611A (en) * | 1994-11-18 | 1997-08-12 | Supratek Pharma Inc. | Polynucleotide compositions |
US5837693A (en) * | 1995-03-24 | 1998-11-17 | The Regents Of The University Of California | Intravenous hormone polypeptide delivery by salivary gland expression |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
EP0863749A2 (fr) * | 1995-11-30 | 1998-09-16 | Vical Incorporated | Lipides cationiques complexes |
US6379966B2 (en) * | 1999-02-26 | 2002-04-30 | Mirus Corporation | Intravascular delivery of non-viral nucleic acid |
US20010031264A1 (en) * | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
US6632436B2 (en) * | 1996-01-25 | 2003-10-14 | Genitrix Llc | Vaccine compositions and method of modulating immune responses |
US5807551A (en) * | 1996-04-01 | 1998-09-15 | Iowa State University Research Foundation, Inc. | Method to provide artificial passive immunity in birds |
US5994317A (en) * | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
GB9610992D0 (en) | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
CA2266656A1 (fr) * | 1996-09-17 | 1998-03-26 | Chiron Corporation | Compositions et procedes de traitement de maladies intracellulaires |
US5861397A (en) * | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
US20020045594A1 (en) * | 1997-02-14 | 2002-04-18 | Merck & Co., Inc. | Polynucleotide vaccine formulations |
US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
GB9726555D0 (en) * | 1997-12-16 | 1998-02-11 | Smithkline Beecham Plc | Vaccine |
CZ302092B6 (cs) * | 1998-02-12 | 2010-10-06 | Immune Complex, Corporation | Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek |
JP2002520299A (ja) | 1998-07-09 | 2002-07-09 | メルク エンド カムパニー インコーポレーテッド | ポリヌクレオチドワクチン配合物 |
GB9906695D0 (en) | 1999-03-24 | 1999-05-19 | Secr Defence | Vaccine composition |
US6586409B1 (en) * | 1999-03-26 | 2003-07-01 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
JP4160201B2 (ja) | 1999-04-21 | 2008-10-01 | 共立製薬株式会社 | コロナウイルス感染症に対するdnaワクチン |
US6696424B1 (en) * | 1999-05-28 | 2004-02-24 | Vical Incorporated | Cytofectin dimers and methods of use thereof |
WO2001034646A2 (fr) | 1999-11-12 | 2001-05-17 | Fibrogen, Inc. | Gelatines de recombinaison |
WO2001080897A2 (fr) * | 2000-04-21 | 2001-11-01 | Vical Incorporated | Compositions pour l'administration in vivo d'agents therapeutiques derives de polynucleotides et methodes associees |
EP1335953A4 (fr) | 2000-06-23 | 2005-03-30 | Merck & Co Inc | Adjuvants de vaccins polynucleotidiques et formulations contenant des tensioactifs cationiques, procedes d'utilisation associes |
AU2001277781A1 (en) | 2000-08-11 | 2002-02-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
EP1427826B1 (fr) | 2001-09-20 | 2011-04-20 | Glaxo Group Limited | Vaccins VIH-RT-nef-Gag à DNA avec codons optimisés |
AU2003293196A1 (en) * | 2002-12-23 | 2004-07-29 | Vical Incorporated | Method for producing sterile polynucleotide based medicaments |
EP1578193A4 (fr) * | 2002-12-23 | 2011-06-15 | Vical Inc | Procede de lyophilisation de complexes d'acide nucleique/copolymere sequence/tensioactif cationique |
JP4723254B2 (ja) * | 2002-12-23 | 2011-07-13 | バイカル インコーポレイテッド | プラスミドdnaを精製するための方法 |
WO2004085650A1 (fr) | 2003-03-24 | 2004-10-07 | The University Of Hong Kong | Essai diagnostique haute vitesse pour la detection du virus humain provoquant le syndrome respiratoire aigu severe (sras) |
US20060257852A1 (en) * | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
WO2004091524A2 (fr) | 2003-04-14 | 2004-10-28 | Acambis Inc. | Vaccins contre des virus des voies respiratoires |
CA2524002C (fr) | 2003-04-15 | 2012-12-18 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Proteines associees au sras |
US8057993B2 (en) | 2003-04-26 | 2011-11-15 | Ibis Biosciences, Inc. | Methods for identification of coronaviruses |
US7897744B2 (en) | 2003-04-28 | 2011-03-01 | The Public Health Agency Of Canada | SARS virus nucleotide and amino acid sequences and uses thereof |
CN1820020B (zh) * | 2003-05-06 | 2010-04-28 | 技术持有有限公司 | Sars-冠状病毒病毒样颗粒以及应用方法 |
CN1548452A (zh) | 2003-05-08 | 2004-11-24 | 清华大学 | Sars冠状病毒的一种膜蛋白及其编码基因与应用 |
US20070092936A1 (en) | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
-
2004
- 2004-05-12 US US10/843,656 patent/US8080642B2/en not_active Expired - Fee Related
- 2004-05-17 WO PCT/US2004/015512 patent/WO2005021707A2/fr active Application Filing
- 2004-05-17 EP EP04776029A patent/EP1633853A4/fr not_active Withdrawn
- 2004-05-17 SG SG2009050212A patent/SG2009050212A/en unknown
- 2004-05-17 CA CA 2526128 patent/CA2526128C/fr not_active Expired - Fee Related
- 2004-05-17 EP EP20100001015 patent/EP2184067B1/fr not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
SG2009050212A (en) | 2014-06-27 |
WO2005021707A2 (fr) | 2005-03-10 |
US20070105193A1 (en) | 2007-05-10 |
CA2526128A1 (fr) | 2005-03-10 |
EP1633853A4 (fr) | 2008-09-24 |
EP2184067A1 (fr) | 2010-05-12 |
EP1633853A2 (fr) | 2006-03-15 |
US8080642B2 (en) | 2011-12-20 |
EP2184067B1 (fr) | 2013-01-23 |
WO2005021707A3 (fr) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2526128C (fr) | Compositions vaccinales d'adn contre le syndrome respiratoire aigu severe et leurs procedes d'utilisation | |
JP5331340B2 (ja) | インフルエンザウィルスワクチン組成物、及びその使用方法 | |
US9161973B2 (en) | Compositions and methods for vaccinating against HSV-2 | |
WO2022110099A1 (fr) | Vaccins à coronavirus et leurs utilisations | |
US20120039935A1 (en) | Methods of treating measles infectious disease in mammals | |
AU2014200035A1 (en) | Compositions and methods for vaccinating against HSV-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170517 |